ArticleBioMed research international2026
Carboxymethylation and Evaluation of Cassava (Manihot esculenta) Starch as a Potential Super-Disintegrant in Tablet Formulations.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carboxymethylation and Evaluation of Cassava (Manihot esculenta) Starch as a Potential Super-Disintegrant in Tablet Formulations.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionCassava (Manihot esculenta) is a significant source of starch in Ethiopia, with potential pharmaceutical applications. However, native starches often require modifications to enhance their utility, particularly as disintegrants. Carboxymethylation is a well-known modification that improves swelling and disintegration capacity. Therefore, this study is aimed at evaluating carboxymethylated cassava starch (CMCS) as a tablet disintegrant.
methodsCMCSs were produced using monochloroacetic acid under varying reaction conditions. Structural modification was confirmed with FTIR spectroscopy. Physicochemical and powder properties, including degree of substitution (DS), swelling power, viscosity, and flow behavior, were characterized using standard methods. Tablets were prepared using the direct compression method. The tablets were assessed for physical characteristics, disintegration, and dissolution to compare the disintegrant performance of CMCS, native cassava starch (NCS), and sodium starch glycolate (SSG).
resultsNine CMCS batches were obtained from the modification process and confirmed by FTIR analysis. CMCSs showed improved characteristics such as hydration capacity, swelling power, and solubility compared to NCS. Specifically, CMCS7 (DS = 0.227) exhibited comparable flow, swelling, hydration, and viscosity to SSG. Thus, it was selected as an optimal batch to be used as a disintegrant. Tablets formulated with CMCS7 exhibited superior mechanical strength, low friability, and higher disintegration efficiency ratios compared to NCS while performing comparably to SSG. Tablets containing CMCS showed comparable disintegration to SSG and enhanced initial dissolution.
conclusionCMCS demonstrated promising disintegrant properties and could serve as a potential alternative local super-disintegrant in pharmaceutical tablet formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.